重组人促红细胞生成素对血液透析患者血浆脂联素水平的影响

Effect of Erythropoietin on Plasma Adiponectin Level in Hemodialysis Patients

[目的]探讨促红细胞生成素（rh-EPO）在血液透析病人中对脂联素水平的影响及意义.[方法]36名维持性血液透析患者用EPO治疗8周,分别在治疗前,治疗第2、4、8周后测定相关指标及脂联素水平.[结果]血液透析患者血清脂联素水平高于正常人;用EPO治疗2周后即出现脂联素水平升高,第4周后脂联素水平进一步升高,第8周与第4周比较无明显变化;应用EPO可降低CRP、SF水平.[结论]EPO可提高血液透析患者脂联素水平,降低C反应蛋白（CRP）、血清铁蛋白（SF）水平,从而降低透析患者心血管疾病的风险.

[Objective] To explore the effect of erythropoietin （EPO） on adiponectin level in hemodialysis patients and its significance. [Methods]Thirty six hemodialysis patients received EPO treatment for 8 weeks. Plasma adiponectin was examined by ELISA before treatment and after treatment for 2, 4 and 8 weeks. [Results] Plasma adiponeetin level was higher in hemodialysis patients than normal people. The level of adiponeetin increased after EPO treatment for 2 weeks, and further increased after treatment for 4 weeks. And there was no significant difference in adiponeetin level between the 8th week and 4th week. The plasma CRP and SF levels were reduced after EPO treatment. [Conclusion] EPO can increase adiponectin levels and decrease CRP and SF levels in hemodialysis patients so as to reduce the risk of cardiovascular disease.